{
  "docId": "019de075-7a24-71be-ac51-dd13871aea0a",
  "docSlug": "fd7a76edfe86a80da6108d342915286a",
  "documentTitle": "BioAtla | Investor Presentation Deck | 43 slides",
  "authorId": "bioatla",
  "authorName": "BioAtla",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 35,
  "pageCount": 43,
  "prevPage": 34,
  "nextPage": 36,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "The slide uses a combination of a summary table for clinical endpoints and a dot plot for NHP toxicity data.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-7a24-71be-ac51-dd13871aea0a/35",
  "deckHref": "/decks/019de075-7a24-71be-ac51-dd13871aea0a",
  "deckJsonHref": "/decks/019de075-7a24-71be-ac51-dd13871aea0a.json",
  "deckAnchorHref": "/decks/019de075-7a24-71be-ac51-dd13871aea0a#slide-35",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.38,
        "x": 0.03,
        "y": 0.215
      },
      "kind": "callout",
      "text": "Research demonstrates challenges and opportunity in combining two Immune Checkpoint Inhibitors: Improves efficacy, but increases adverse events; Greater % of patients discontinue therapy relative to monotherapy",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "484b4551-88fb-499f-a29f-25e63c2016e2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.5,
        "x": 0.46,
        "y": 0.52
      },
      "kind": "chart",
      "text": "NHP study toxicity dot plot comparing Vehicle Control, Nivo + Ipi, and Nivo + CAB-BA3071",
      "attrs": null,
      "subkind": "dot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9aff2971-b60e-4ac0-93e9-1e2f289d0cf9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.38,
        "x": 0.03,
        "y": 0.56
      },
      "kind": "paragraph",
      "text": "In NHP study, BA3071 achieved similar exposure levels to Ipi analog with significantly less toxicity in combination with nivo",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "74a6049b-48dc-467b-a775-fb02c61440ec",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.1,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "*Larkin et al., New Eng. J. Med.,373: 23-34, 2015; **Chang et al., PNAS 118 (9): 1-10, 2021. Nivo: 20mg/kg QW (12X human dose); Ipi or CAB-CTLA: 15mg/kg QW (45 – 60X human dose). AUC168 = Area under the serum drug concentration-time curve from time zero to 168 hours; Cmax = Highest drug concentration observed in serum",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "411ae3f3-8b1a-4c1d-8ff0-6da55e075875",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.5,
        "x": 0.46,
        "y": 0.24
      },
      "kind": "table",
      "text": "Clinical Endpoint | Nivolumab (PD-1) | Nivolumab (PD-1) + Ipilimumab (CTLA4) | Progression Free Survival | 6.9 months | 11.5 months | Grade 3 or 4 Adverse Events | 16.3% | 55.0% | Discontinued Treatment | 7.7% | 36.4%",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3b1de8f0-6913-47ce-a69c-797f2028948f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.5,
        "x": 0.03,
        "y": 0.14
      },
      "kind": "title",
      "text": "Best-in-class and potential for disruption of the I/O Market",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "01306f17-b61d-4d21-b9b0-7d59ac3ee90f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "BA3071 (CAB-CTLA-4)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e64603d6-c522-4f05-8100-2f4313a316e5",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "5586eab2-f3a4-47ef-8b21-a01476dfd378",
      "evidence": "table/data: Clinical Endpoint | Nivolumab (PD-1) | Nivolumab (PD-1) + Ipilimumab (CTLA4) | Progression Free Survival | 6.9 months | 11.5 months | Grade 3 or 4 Adverse Events | 16.3% | 55.0% | Discontinued Treatment | 7.7",
      "confidence": 0.9
    }
  ],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "27b5f773-676a-481d-afa0-8ce988cd31eb",
      "evidence": "Compares standard of care vs new drug candidate across clinical endpoints and toxicity",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 40,
      "from": 8,
      "beatId": "e2a4fdc0-9030-4acb-8ef9-b3ca594561cc",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Roadmap",
      "beatSlug": null,
      "evidence": "The deck outlines a clear roadmap for BioAtla's pipeline and milestones",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}